| Autor: |
Maldov DG; ZAO SKY LTD, Moscow, Russia. maldov-dg@yandex.ru., Andronova VL; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia., Grigorian SS; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia., Isaeva EI; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia., Deryabin PG; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia., Mishin DV; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia., Balakina AA; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia., Ilyichev AV; ZAO SKY LTD, Moscow, Russia., Terentyev AA; Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia., Galegov GA; Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health, Moscow, Russia. |
| Abstrakt: |
Stimforte, an immune response-stimulating preparation, is active with respect to hepatitis C virus (HCV) and herpes simplex virus type I (HSV-1). The effects of Stimforte in animals infected with either HCV or HSV-1 are fundamentally different. In mice with acute herpes virus infection, Stimforte administration leads to a higher activity of natural killer cells and cytotoxic lymphocytes, and the amount of interferon (IFN) λ grows. In mice infected with HCV, Stimforte administration results in a significant increase in IFN-β but not IFN-λ in blood and affected organs. Stimforte has been found to affect directly HCV reproduction that causes the infected cell death, but it does not affect HSV-1 reproduction in the Vero cells (V). |
Full text from SpringerLink